Back to Journals » Infection and Drug Resistance » Volume 12

Quinolones and fluoroquinolones are useless to counter uropathogenic Escherichia coli infections [Letter]

Authors Singh BR

Received 21 June 2019

Accepted for publication 3 July 2019

Published 18 July 2019 Volume 2019:12 Pages 2161—2162


Checked for plagiarism Yes

Editor who approved publication: Professor Suresh Antony

Download Article [PDF] 

Bhoj R Singh

Division of Epidemiology, The Indian Council of Agricultural Research-Indian Veterinary Research Institute, Izatnagar, 243122, India

In the study by Malekzadegan et al,1 conducted on a limited number of cases, it is reported that 71.9% and 48.4% of isolates of uropathogenic Escherichia coli were resistant to nalidixic acid and ciprofloxacin, respectively.

View the original paper by Malekzadegan and colleagues.

A response to the letter has been published 

In the study by Malekzadegan et al,1 conducted on a limited number of cases, it is reported that 71.9% and 48.4% of isolates of uropathogenic Escherichia coli were resistant to nalidixic acid and ciprofloxacin, respectively. It appears of normal occurrence but certainly enriches the knowledge of clinicians towards the selection of appropriate antibiotic. In the study, E. coli isolates claimed to be uropathogenic were not confirmed for their uropathogenic potential with any other test than their isolation in pure culture from urinary tract infection (UTI) cases. Uropathogenic E. coli may also occur in mixed culture and sometimes may be just contaminants from perineal region.2 My intention is not to criticise the report but I feel that people in Iran are certainly lucky not to have super-drug-resistant E. coli causing urinary tract infections. In Bareilly, one of the big city in India, on looking at bacteriological culture and antibiotic sensitivity data of recent 209 human UTI cases referred to Clinical Epidemiology Laboratory of the Institute, E. coli was at the top to be associated with urinary tract infections in 22% cases, followed staphylococci (20.6%), streptococci (10.5%), enterococci (8.1%), Enterobacter sp. (6.2%), Proteus sp. (4.3%), Aerococcus sp. (3.8%), Erwinia sp. (3.8%), klebsiellae (3.3%), pseodomonads (2.9%), Raoultella sp. (2.9%), Acinetobacter sp. (1.9%), Alcaligenes sp. (1.9%), aeromonads (1.4%), Flavobacter sp. (1%), Micrococcus sp. (1%) strains, and isolation of Actinobacillus, Bacillus, Candia, Citrobacter, Edwardsiella, Moraxella, Morganella, Serratia and Vibrio species from one case each was also recorded.

Of the 46 isolates of E. coli, isolated in our laboratory from UTI cases, all were resistant to nalidixic acid, only 13% were sensitive for ciprofloxacin and 7 of them were also resistant to one or more carbapenem drugs (producing Metallo-β-lactamase); however, nitrofurantoin, a drug of choice earlier in UTI cases, was found inhibitory to >90% strains of E. coli from UTI cases.

I feel that there is a continuous need for monitoring of E. coli and other bacteria too causing UTI and gastrointestinal tract infections to keep an eye on the emergence of drug-resistant strains as such E. coli strains have a high potential of spread beyond geographical boundaries through excretions of travellers either clinically ill or carriers of the potentially pathogenic strains.


The author reports no conflicts of interest in this communication.


1. Malekzadegan Y, Rastegar E, Moradi M, Heidari H, Sedigh Ebrahim-Saraie H. Prevalence of quinolone-resistant uropathogenic Escherichia coli in a tertiary care hospital in south Iran. Infect Drug Resist. 2019;12:1683–1689. doi:10.2147/IDR.S206966

2. Stork C, Kovács B, Rózsai B, et al. Characterization of asymptomatic bacteriuria Escherichia coli isolates in search of alternative strains for efficient bacterial interference against uropathogens. Front Microbiol. 2018;9:214. doi:10.3389/fmicb.2018.00214

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]